Agenus shared a post on LinkedIn:
“Today we shared our Q1 2025 financial results and highlighted key updates from our immuno-oncology pipeline, including the latest data on botensilimab and balstilimab in the neoadjuvant setting across solid tumors.
We remain committed to advancing the next generation of immunotherapies for individuals living with cancer.
Access the Q1 report.”
More posts featuring Immuno-Oncology on OncoDaily.